Novo Nordisk has entered a $550 million multi-year collaboration with Replicate Bioscience to develop novel therapeutics targeting obesity, type 2 diabetes, and cardiometabolic conditions using Replicate’s self-replicating RNA (srRNA) platform. This technology allows for durable, tunable therapeutic protein expression, with the partnership aiming to accelerate innovation and expand Novo Nordisk's pipeline in metabolic disorders.